Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
City of Hope Medical Center
AHS Cancer Control Alberta
Weill Medical College of Cornell University
Petrov, Andrey
Emory University
Northwell Health
Northwell Health
Precision Life Sciences Group
Universitätsmedizin Mannheim
Cortice Biosciences, Inc.
InSightec
National Cancer Institute (NCI)